Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00205725 · ClinicalTrials.gov registry record · NA
Pfizer/IVGTT/Ziprasidone/Olanzapine
A NA study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 120
- Enrollment target
NCT00205725 is a NA study that has completed, run by Washington University School of Medicine. The registered enrollment target is 120 participants.
The verdict
NCT00205725, a NA study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
Study Summary
Abnormalities in peripheral glucose regulation and type 2 diabetes can occur more commonly in individuals with schizophrenia than in healthy subjects or in other psychiatric conditions. Antipsychotic treatment may contribute significantly to abnormalities in glucose regulation. Hyperglycemia can contribute to long-term cardiovascular disease risk that may already be increased in patients with schizophrenia due to higher rates of smoking, sedentary life style, obesity and under-treated hypertension and dyslipidemia. This project will characterize the effects on glucose control of the two most commonly prescribed newer antipsychotic medications, ziprasidone and olanzapine, in patients with schizophrenia.
Interventions
- DRUG Ziprasidone, Olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2000-11 |
| Est. Completion | 2006-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00205725
The ClinicalTrials.gov registry entry for NCT00205725 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ziprasidone, Olanzapine is the first listed.
NCT00205725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00205725 about?
NCT00205725 is a clinical study titled "Pfizer/IVGTT/Ziprasidone/Olanzapine". Abnormalities in peripheral glucose regulation and type 2 diabetes can occur more commonly in individuals with schizophrenia than in healthy subjects or in other psychiatric conditions. Antipsychotic treatment may contribute significantly to abnormalities in glucose regulation. Hyperglycemia can con...
What is the current status of trial NCT00205725?
This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2000-11. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00205725?
The interventions under investigation include: Ziprasidone, Olanzapine (DRUG).
Who is sponsoring clinical trial NCT00205725?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.